Pinealon
EDR peptide, Glu-Asp-Arg, EDR tripeptide
Pinealon is a three-amino-acid peptide from the Khavinson series, derived by amino acid analysis of brain and pineal tissue extracts and promoted for cognitive protection and circadian regulation. The published record runs to roughly twenty PubMed-indexed papers, almost all from the originating Russian institute, covering cell culture and rodent models. There is no controlled human trial.
Mechanism
Pinealon is a tripeptide with no identified receptor. The Khavinson group's model is that peptides this small enter the nucleus unaided and bind directly to DNA, with sequence-selective recognition of promoter regions, thereby regulating transcription. Supporting this, fluorescently labelled EDR has been shown to distribute into HeLa cell cytoplasm, nucleus and nucleolus and to quench the fluorescence of labelled deoxyribo-oligonucleotides with constants that differ by sequence and by cytosine methylation status. Whether that binding is specific enough at physiological concentrations to explain a biological effect remains unestablished. The 'unaided entry' premise has also been undercut from within the same group: a 2023 modelling and docking study proposed instead that EDR and 25 related ultrashort peptides are efficient ligands of the LAT1, LAT2 and PEPT1 membrane transporters, which is a materially different account of how these molecules cross membranes.
The proposed downstream biology is neuroprotective. In cell culture, EDR has been reported to restrict reactive oxygen species accumulation in cerebellar granule cells, neutrophils and PC12 cells under oxidative stress, to reduce necrotic cell death, and to alter the timing of ERK1/2 activation and the cell cycle. Work published in Molecules proposed that EDR regulates expression of genes implicated in Alzheimer's disease pathogenesis.
It is worth being clear that the DNA-binding model is a hypothesis put forward by one group, not an established mechanism. It has not been independently validated by structural biology in the way that would normally be required before a transcriptional mechanism is accepted, and the concentrations used in the in vitro binding experiments are far above what a short peptide would plausibly reach in tissue.
What the research shows
The pinealon literature amounts to roughly twenty PubMed-indexed records, and the great majority carry Khavinson or close collaborators as authors. The most substantive cell work, published in Rejuvenation Research in 2011, reported dose-dependent restriction of reactive oxygen species accumulation and reduced necrotic cell death across three cell types under oxidative stress. That paper concluded that 'besides its known antioxidant activity, pinealon is able to interact directly with the cell genome', an inference drawn from the observation that ROS effects saturated at lower concentrations than cell-cycle effects. That is a reasonable hypothesis but it is not a demonstration of genome interaction, and it should not be quoted as one. Animal work includes a study in which Pinealon administered to pregnant rats protected offspring from the effects of prenatal hyperhomocysteinaemia, reducing oxidative damage markers in brain tissue.
Human data are effectively absent. Russian-language papers in Advances in Gerontology report neuroprotective or anti-ageing effects of peptide bioregulators in people of various ages, but these are small, unblinded, uncontrolled or poorly controlled, published in a journal with limited international readership, typically administer several peptides together so no compound-specific inference is possible, and have not been replicated. They do not constitute evidence for Pinealon specifically. There is no registered clinical trial of Pinealon anywhere.
The pattern here is the same across the Khavinson tripeptide and tetrapeptide series: a body of internally consistent work from a single institute, a mechanistic model that has not been independently validated, and a marketing presentation that treats decades of accumulation as though it were replication. Volume of publication and independence of replication are different things, and only the second one licenses confidence.
Evidence assessment
Preclinical only
Evidence is limited to cell culture and rodent studies almost entirely from one research group; the small Russian human reports are uncontrolled, administer multiple peptides together and permit no compound-specific conclusion.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes Preclinical only
EDR produced dose-dependent restriction of reactive oxygen species accumulation and decreased necrotic cell death, accompanied by delayed ERK1/2 activation and cell cycle modification.
Pinealon protects the rat offspring from prenatal hyperhomocysteinemia Preclinical only
Maternal Pinealon administration reduced oxidative damage markers in offspring brain tissue.
EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease Preclinical only
Proposed that EDR regulates transcription of genes implicated in Alzheimer's pathogenesis via direct DNA interaction.
Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA Preclinical only
Labelled pinealon (EDR), epithalon (AEDG) and testagen (KEDG) were detected in HeLa cytoplasm, nucleus and nucleolus, with quenching constants indicating sequence- and methylation-dependent binding to oligonucleotides.
Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters Preclinical only
EDR was among the peptides scoring most efficiently as a ligand of these transporters, leading the authors to propose transporter-mediated cellular uptake.
Neuroprotective effects of peptide bioregulators in people of various age Limited evidence
Reported neuroprotective effects of peptide bioregulators across age groups.
Safety
No formal safety characterisation. No toxicology study, no human adverse event data, no dose-ranging. The absence of reported harm reflects the absence of systematic study. Material sold online is unregulated, and identity, purity, sterility and endotoxin content are unverified.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. Supply for human use engages the Human Medicines Regulations 2012 regardless of a 'research use only' label. |
| United States | Not approved by the FDA and never studied under an investigational new drug application. Sold as a research chemical, a commercial disclaimer rather than a regulatory category. |
| WADA (sport) | Not individually named on the Prohibited List but captured by section S0 (non-approved substances), prohibited at all times. |
Questions
No controlled human evidence. Small Russian-language reports in Advances in Gerontology describe neuroprotective or anti-ageing effects in people, but they are uncontrolled, unblinded and administer several peptides together, so nothing can be attributed to Pinealon. No registered clinical trial of the compound exists.
The Khavinson group proposes that tripeptides are small enough to enter the cell nucleus unaided and bind directly to promoter DNA, switching specific genes on or off. In vitro work shows short peptides can be found in nuclei and bind DNA, but the concentrations used are far above physiological, the mechanism has not been independently validated, and the same group's later modelling work proposes transporter-mediated uptake instead.
No. Pinealon is the tripeptide Glu-Asp-Arg (EDR); Epitalon is the tetrapeptide Ala-Glu-Asp-Gly (AEDG). Both come from the same Russian research programme and share the same proposed mechanism, but they are different molecules with different reported targets.
Around twenty PubMed-indexed papers, almost all authored by the originating institute or close collaborators. No independent Western laboratory has replicated the core findings.